Glox Therapeutics Ltd. has raised £4.3 million (US$5.37 million) in seed funding to develop targeted therapeutics against antibiotic-resistant gram-negative bacteria. The company was founded earlier this year as a spin-out from the Universities of Glasgow and Oxford.
National Taiwan University researchers reported the identification of a novel sorafenib derivative, SCB-24, which has the potential to be a new antimicrobial therapeutic.
Kaken Pharmaceutical Co. Ltd. and Bitbiome Inc. have entered into an agreement to collaborate on the creation of new drugs targeting infectious diseases with unmet medical needs.
Investigators working at the Jiangxi Science & Technology Normal University, China, have reported the development of novel ruthenium polypyridine antibiotics with demonstrably promising in vitro and in vivo activity against Staphylococcus aureus.
The U.S. FDA’s approval, in recent years, of new medicines that can fight certain drug-resistant bugs makes it possible to conduct noninferiority trials of potential antibacterial therapies in patients with infections caused by those bugs since active controls are now available.
Alopexx Inc. filed for an IPO that would bank as much as $17 million to continue the firm’s investigations of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
PARIS – Spartha Medical SAS reported an award of $2.7 million in grants with further, undisclosed equity financing from the European Innovation Council (EIC) Fund, a body run by the European Commission established to make direct equity investment in European Union companies. This fund will be used to initiate clinical evaluation of its multifunctional coating technique.
